Literature DB >> 23299964

Pleurodesis outcome in malignant pleural mesothelioma.

Edward Thomas Hamilton Fysh1, Sze Khen Tan, Catherine Ann Read, Felicity Lee, Kate McKenzie, Nola Olsen, Indunil Weerasena, Timothy Threlfall, Nicholas de Klerk, A William Musk, Y C Gary Lee.   

Abstract

Few data exist on the pleurodesis outcome in patients with malignant pleural mesothelioma (MPM). A retrospective review of the Western Australian Mesothelioma Registry over 5 years revealed 390 evaluable patients. Only a subset of patients (42.3%) underwent pleurodesis, surgically (n=78) or by bedside instillation of sclerosants (n=87). Surgical pleurodesis showed no advantages over bedside pleurodesis in efficacy (32% vs 31% failures requiring further drainage, p=0.98), patient survival (p=0.52) or total time spent in hospital from procedure till death (p=0.36). No clinical, biochemical or radiographic parameters tested adequately predict pleurodesis outcome.

Entities:  

Keywords:  Mesothelioma; Pleural Disease; Thoracic Surgery

Mesh:

Substances:

Year:  2013        PMID: 23299964     DOI: 10.1136/thoraxjnl-2012-203043

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  11 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 2.  Landmark Trials in the Surgical Management of Mesothelioma.

Authors:  Taylor Kantor; Elliot Wakeam
Journal:  Ann Surg Oncol       Date:  2021-01-31       Impact factor: 5.344

3.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

4.  Protocol of the Australasian Malignant Pleural Effusion (AMPLE) trial: a multicentre randomised study comparing indwelling pleural catheter versus talc pleurodesis.

Authors:  Edward T H Fysh; Rajesh Thomas; Catherine A Read; Ben C H Kwan; Ben C H Lam; Elaine Yap; Fiona C Horwood; Pyng Lee; Francesco Piccolo; Ranjan Shrestha; Luke A Garske; David C L Lam; Andrew Rosenstengel; Michael Bint; Kevin Murray; Nicola A Smith; Y C Gary Lee
Journal:  BMJ Open       Date:  2014-11-06       Impact factor: 2.692

5.  Complications of indwelling pleural catheter use and their management.

Authors:  Macy M S Lui; Rajesh Thomas; Y C Gary Lee
Journal:  BMJ Open Respir Res       Date:  2016-02-05

Review 6.  Contemporary best practice in the management of malignant pleural effusion.

Authors:  Coenraad F N Koegelenberg; Jane A Shaw; Elvis M Irusen; Y C Gary Lee
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

7.  Comparison of efficacy and toxicity between nedaplatin and cisplatin in treating malignant pleural effusion.

Authors:  Li-Zhe Zhong; Hong-Yan Xu; Zhong-Min Zhao; Guang-Mei Zhang; Feng-Wu Lin
Journal:  Onco Targets Ther       Date:  2018-09-05       Impact factor: 4.147

8.  Does attempting talc pleurodesis affect subsequent indwelling pleural catheter (IPC)-related non-draining septated pleural effusion and IPC-related spontaneous pleurodesis?

Authors:  Rachelle Asciak; Rachel M Mercer; Robert J Hallifax; Maged Hassan; Eihab Bedawi; David McCracken; Nikolaos I Kanellakis; John M Wrightson; Ioannis Psallidas; Najib M Rahman
Journal:  ERJ Open Res       Date:  2019-02-01

Review 9.  Complications of thoracoscopic talc insufflation for the treatment of malignant pleural effusions: a meta-analysis.

Authors:  Wen Zhang; Yun-Long Zhao; Shao-Jun Li; Ying-Nan Zhao; Nan-Nan Guo; Bo Liu
Journal:  J Cardiothorac Surg       Date:  2021-05-04       Impact factor: 1.637

Review 10.  Surgical treatment in malignant pleural effusion.

Authors:  Şule Karadayı; Ekber Şahin
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2021-10-20       Impact factor: 0.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.